• Mechanism Of Action
  • Unique Adc Design

TRODELVY 200mg

Mechanism Of Action

TRODELVY: the first and only approved TROP-2-directed ADC1

approved TROP-2-directed ADC

Activity for TRODELVY was noted across TROP-2 expression levels and therefore TROP-2 testing is not required for treatment initiation with TRODELVY10,11

ABBREVIATIONS:

2L, second line; ADC, antibody-drug conjugate; mAb, monoclonal antibody; mTNBC, metastatic triple-negative breast cancer; TROP-2, trophoblast antigen 2.

REFERENCES:

  1. Bardia A, et al. Presented at the Virtual 2020 ESMO Congress.
  2. Rugo HS, et al. Future Oncol. 2020;16(12):705–715.
  3. Goldenberg DM, et al. Oncotarget. 2015;6(26):22496–22512.
  4. Stepan LP, et al. J Histochem Cytochem. 2011;59(7):701–710.
  5. Shvartsur A, et al. Genes Cancer. 2015;6(3-4):84–105.
  6. Bardia A, et al. N Engl J Med. 2021;384(16):1529–1541.
  7. Goldenberg DM, et al. Exp Opin Biol Ther. 2020;20(8):871–885.
  8. Sharkey RM, et al. Clin Cancer Res. 2015;21(22):5131–5138.
  9. Cardillo TM, et al. Clin Cancer Res. 2011;17(10):3157-3169.
  10. Loriot Y, et al. Presented at the Virtual 2020 ESMO Congress.
  11. TRODELVY (sacituzumab govitecan) Summary of Product Characteristics, February 2023.